Clostridioides difficile toxA Specific Neutra™ Antibody Products

Are you currently facing challenges in antibody development for gastrointestinal pathogens or experiencing difficulty in neutralizing the potent effects of Clostridioides difficile toxins in complex clinical models? Our C. difficile toxA Specific Neutra™ Antibody Products help you develop highly specific therapies and diagnostic tools through advanced recombinant DNA technology and high-affinity neutralizing platforms. By targeting the critical functional domains of TcdA, Creative Biolabs provides the precision required to mitigate epithelial damage and streamline your biopharmaceutical development.

Introduction of C. difficile toxA

Clostridioides difficile toxin A (TcdA) is a massive, 308 kDa exotoxin that serves as a primary virulence factor in C. difficile infection (CDI). Together with Toxin B (TcdB), TcdA is responsible for the clinical manifestations of antibiotic-associated diarrhea and pseudomembranous colitis.

Structure and Mechanism

TcdA is a multi-domain protein consisting of:

• Glucosyltransferase Domain (GTD): The N-terminal enzymatic region that inactivates Rho family GTPases.
• Cysteine Protease Domain (CPD): Responsible for the autocatalytic cleavage and release of the GTD into the host cytosol.
• Transmembrane Domain (TMD): Facilitates the translocation of the toxin across the endosomal membrane.
• Combined Repetitive Oligopeptide (CROP) Domain: The C-terminal region responsible for binding to cell-surface receptors such as glycoprotein 96 (gp96) and sulfated glycosaminoglycans.

Fig.1 Mechanism of action of TcdA and TcdB.¹

Pathogenic Signaling

Once internalized, TcdA covalently glucosylates Rho, Rac, and Cdc42 GTPases. This modification disrupts the actin cytoskeleton, leading to "cell rounding," loss of tight junction integrity, and massive fluid secretion. The resulting inflammation and neutrophil recruitment characterize the severe mucosal damage seen in CDI.

Clinical Impact

CDI is a significant global health burden, often recurring in up to 25% of patients after standard antibiotic treatment. Because TcdA targets the intestinal epithelium directly, neutralizing its activity is a critical strategy for preventing primary and recurrent disease.

Applications of anti C. difficile toxA Neutralizing Antibodies

Neutralizing antibodies against TcdA are essential across various sectors of biopharmaceutical research:

• Therapeutic Development: Used in combination with TcdB-targeting antibodies to provide comprehensive protection against hypervirulent C. difficile strains.
• Passive Immunization Studies: Investigating the efficacy of oral or systemic delivery to prevent CDI recurrence in high-risk populations.
• Diagnostic Assay Development: Serving as the capture or detection element in high-sensitivity Immunoassays to distinguish between colonization and active infection.
• Mechanistic Research: Employed as tools to block specific toxin domains in vitro to study the kinetics of pore formation and cellular uptake.

Our Anti C. difficile toxA Neutralizing Antibodies

Creative Biolabs provides a diverse portfolio of C. difficile toxA Specific Neutra™ Antibodies designed for high-performance research:

• Neutra-TcdA Monoclonals: High-affinity mouse and rabbit monoclonals validated for neutralization assays (IC50 characterization) and structural biology.
• Humanized Lead Candidates: Recombinant antibodies designed for cross-reactivity with multiple clinical ribotypes.
• Detection Grade Conjugates: Biotinylated or FITC-labeled anti-TcdA antibodies for rapid screening in complex matrices.
• High-Quality Research Benchmarks: Reference-grade neutralizing antibodies to facilitate comparative efficacy studies and benchmarking of novel therapeutic leads.

Our antibodies undergo rigorous quality control, including epitope mapping and stability testing, ensuring that your results are reproducible and clinically relevant.

Creative Biolabs is dedicated to providing the most advanced antibody solutions to combat C. difficile infections. Our C. difficile toxA Specific Neutra™ Antibody Products empower your research with high-precision tools for neutralization, detection, and therapeutic discovery.

To learn more about our product specifications or to request a custom bulk quote, please visit our contact page or speak directly with our immunology specialists.

Contact Our Team for More Information and to Discuss Your Project

Reference

1. Pourliotopoulou, Evdokia et al. "Exploring the Toxin-Mediated Mechanisms in Clostridioides difficile Infection." Microorganisms vol. 12,5 1004. 16 May. 2024, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/microorganisms12051004